Trial Profile
The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jul 2021
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Choroidal neovascularisation
- Focus Registrational; Therapeutic Use
- Acronyms SHINY
- Sponsors Chengdu Kanghong Biological Science & Technology
- 01 Sep 2014 New trial record